Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Expected to Rise, UBS Group Analyst Says

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective upped by stock analysts at UBS Group from $306.00 to $307.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. UBS Group’s price target would indicate a potential upside of 60.32% from the company’s current price.

ASND has been the topic of several other research reports. Evercore ISI upped their price objective on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an “outperform” rating in a report on Friday, May 2nd. JPMorgan Chase & Co. upped their price objective on shares of Ascendis Pharma A/S from $245.00 to $254.00 and gave the company an “overweight” rating in a report on Tuesday, July 29th. Oppenheimer restated an “outperform” rating and set a $224.00 price objective (up previously from $215.00) on shares of Ascendis Pharma A/S in a report on Friday, June 13th. Cantor Fitzgerald upped their price objective on shares of Ascendis Pharma A/S from $200.00 to $203.00 and gave the company an “overweight” rating in a report on Friday. Finally, Wells Fargo & Company restated an “overweight” rating and set a $295.00 price objective (up previously from $289.00) on shares of Ascendis Pharma A/S in a report on Friday. Sixteen investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $239.80.

Ascendis Pharma A/S Stock Performance

Shares of Ascendis Pharma A/S stock opened at $191.49 on Friday. The company has a market capitalization of $11.71 billion, a PE ratio of -37.11 and a beta of 0.41. The company has a 50-day simple moving average of $174.03 and a two-hundred day simple moving average of $159.06. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $199.99.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) EPS for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.49. The firm had revenue of $216.28 million during the quarter, compared to the consensus estimate of $163.17 million. On average, equities analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several hedge funds have recently bought and sold shares of the stock. Virtus ETF Advisers LLC boosted its position in Ascendis Pharma A/S by 3.9% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,676 shares of the biotechnology company’s stock worth $368,000 after purchasing an additional 100 shares in the last quarter. Gilbert & Cook Inc. raised its stake in Ascendis Pharma A/S by 2.0% in the 2nd quarter. Gilbert & Cook Inc. now owns 6,750 shares of the biotechnology company’s stock valued at $1,165,000 after purchasing an additional 131 shares during the last quarter. Chicago Partners Investment Group LLC raised its stake in Ascendis Pharma A/S by 4.5% in the 2nd quarter. Chicago Partners Investment Group LLC now owns 3,732 shares of the biotechnology company’s stock valued at $635,000 after purchasing an additional 161 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Ascendis Pharma A/S by 2.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 8,578 shares of the biotechnology company’s stock worth $1,337,000 after acquiring an additional 195 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Ascendis Pharma A/S in the 4th quarter worth $28,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.